<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23291185</PMID>
        <DateCompleted>
            <Year>2013</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1090-2104</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>431</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Feb</Month>
                        <Day>08</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochemical and biophysical research communications</Title>
                <ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>274-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2012.12.118</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0006-291X(12)02478-3</ELocationID>
            <Abstract>
                <AbstractText>Osteosarcoma (OS) is one of the most common malignant bone tumors in early adolescence. Multi-drug chemotherapy has greatly increased the five year survival rate from 20% to 70%. However, the rate has been staggering for 30 years and the prognosis is particularly poor for patients with recurrence and metastasis. Our study aimed to investigate the role of Wnt-β-catenin, Notch and Hedgehog pathway in OS development because all these pathways are involved in skeletal development, tumorigenesis and chemoresistance. Our results showed that the major components in Wnt-β-catenin pathway, e.g. Wnt3a, β-catenin and Lef1, were consistently upregulated in human osteosarcoma cell line Saos2 cells compared to human fetal osteoblasts (hFOB), whereas the changes in the expression levels of Notch and Hh signaling molecules were not consistent. Knocking down β-catenin increased the Saos2 sensitivity to methotrexate (MTX) induced cell death. Consistently, the expression level of β-catenin protein correlated with the invasiveness of OS, as evidenced by more intensive β-catenin immunoreactivity in higher grade OS samples. Chemical inhibition of the Wnt-β-catenin signaling enhanced MTX mediated death of Saos2 cells. A synergistic effect with MTX was observed when both inhibitors for Wnt-β-catenin and Notch pathways were simultaneously used, while the addition of the Hh inhibitor did not further improve the efficacy. Our findings provide some novel insight to OS pathogenesis and lay a foundation for future application of Wnt-β-catenin and Notch inhibitors together with the currently used chemotherapeutic drugs to improve the outcome of OS treatment.</AbstractText>
                <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Yimin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopaedics, The First Affiliated Hospital, Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Yongxin</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Ethan Q</ForeName>
                    <Initials>EQ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Huiwu</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Di</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobs</LastName>
                    <ForeName>Joshua J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gitelis</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Keefe</LastName>
                    <ForeName>Regis J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Konttinen</LastName>
                    <ForeName>Yrjö T</ForeName>
                    <Initials>YT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Guoyong</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Tian-Fang</ForeName>
                    <Initials>TF</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 AR054465</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR055915</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>01</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biochem Biophys Res Commun</MedlineTA>
            <NlmUniqueID>0372516</NlmUniqueID>
            <ISSNLinking>0006-291X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051153">Wnt Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053823" MajorTopicYN="N">Hedgehog Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012516" MajorTopicYN="N">Osteosarcoma</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051153" MajorTopicYN="N">Wnt Proteins</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>12</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>1</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23291185</ArticleId>
            <ArticleId IdType="pii">S0006-291X(12)02478-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbrc.2012.12.118</ArticleId>
            <ArticleId IdType="pmc">PMC3710725</ArticleId>
            <ArticleId IdType="mid">NIHMS481541</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Ther. 2010 Mar;9(3):731-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20197388</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2010 Jan;220(1):24-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19882675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2010 May 20;29(20):2916-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20208568</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2010 Jun 1;70(11):4602-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20460510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Oncol Rep. 2010 Jul;12(4):266-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20473649</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2010 Jul;11(7):670-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20347613</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Anticancer Ther. 2010 Aug;10(8):1313-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20735316</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20943636</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Adv Hematol Oncol. 2010 Oct;8(10):705-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21317869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 2011 Jun;224(2):169-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21506130</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Rev Anticancer Ther. 2011 Aug;11(8):1223-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21916576</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 2011 Oct;38 Suppl 3:S19-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22055968</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Med. 2012 Mar;29(3):423-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22138977</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Exp Metastasis. 2003;20(6):525-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14598886</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2004 Mar10;109(1):106-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14735475</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Apr 15;64(8):2734-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15087387</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2005 Feb;6(2):85-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15683817</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Oncol. 2007 Jul;19(4):341-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17545797</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Chemother. 2007 Oct;19(5):554-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18073155</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 May 15;14(10):2962-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18483362</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 2008 Mar-Apr;28(2A):673-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18507006</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Dev. 2008 Jun 15;22(12):1662-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18559481</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Paediatr Drugs. 2008;10(5):315-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18754698</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hum Mol Genet. 2009 Apr 15;18(8):1464-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19228774</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Invest. 2009 Apr;119(4):837-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19307728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2009 Jun 16;100(12):1957-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19455146</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Carcinogenesis. 2009 Oct;30(10):1789-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19635748</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Treat Options Oncol. 2009 Apr;10(1-2):82-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19238553</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Acad Orthop Surg. 2009 Aug;17(8):515-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19652033</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann N Y Acad Sci. 2010 Mar;1192:257-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20392245</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>